- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04615741
Finding Wellness in the Pandemic
Improving Health and Wellness During COVID-19
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Lethbridge, Alberta, Canada, T1K 3M4
- University of Lethbridge
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women between 18-75 years living in Alberta, Canada
- Need to have reliable access to the internet, a device with a webcam for the next 2 months
- Need to self-identify that they are currently struggling with at least one of: stress eating, alcohol use, drug use, tobacco use, or gambling during the pandemic
Exclusion Criteria:
- Non-community dwelling
- Do not currently reside within Alberta, Canada
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Trauma Informed Yoga
Participants will receive 8 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
|
One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions.
Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds.
The instructor will begin the class by introducing the week's theme (e.g.
grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
|
EXPERIMENTAL: Trauma Informed Psychotherapy
Participants will receive 8 x 90 min group-based psychotherapy sessions, delivered synchronously over Zoom.
|
Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program.
Facilitators will begin the session by introducing the week's theme (e.g.
setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g.
large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
|
NO_INTERVENTION: Control
These participants will not receive an intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Tobacco Use
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Participants will be asked to self-report if tobacco use has changed during the pandemic via a 5-point likert.
Options range from increased a lot to decreased a lot.
If participants indicate their tobacco use has changed, they will be asked to identify the primary reason for this change.
Changes in tobacco use will be re-assessed at each time point.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Alcohol Use
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Past year alcohol consumption will be assessed through the Alcohol Use Disorder Identification Test (AUDIT).
Scores on the AUDIT range from 0 to 40; a score over 8 is indicative of problematic or hazardous alcohol use.
Changes in alcohol consumption since the beginning of the pandemic will be identified through a 5-point likert.
Changes in alcohol use will be re-assessed at each time point.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Drug Use
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Past year drug use will be assessed through the Drug Use Disorders Identification Test (DUDIT).
Possible scores on the DUDIT range from 0 to 44; scores greater than 2 or 6 are indicative of risky or harmful drug habits for women and men, respectively.
A score of 25 or more suggests the individual is probably heavily dependent on drugs.
Participants will also be asked to identify which drugs they currently use, the main reasons for using drugs, and whether their drug use has changed during the pandemic.
Changes in drug use will be re-assessed at each time point.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Gambling
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Gambling will be assessed via the 9-item Problem Gambling Severity Index (PGSI).
The items are measured on a 5-point likert with frequencies from "less than once a month" to "daily or almost daily".
A cut-score ≥5 will be used (lower scores indicative of non-problem gambling); the PGSI has a high internal consistency (α = 0.86) and is considered the measure of choice for non-clinical use.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Post-Traumatic Stress Symptoms
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
A revised version of the Primary Care - Post Traumatic Stress Disorder - 5 (PC-PTSD-5) scale will be assessed to determine experiences of trauma in relation to COVID-19.
The scale was revised to specifically ask about COVID-19.
Scores range from 0 (no risk) to 5 (high risk).
A cut-score of 3 will be used to differentiate high- and low-risk scores.
The PC-PTSD has good sensitivity (r = 0.78) and sensitivity (r = 0.87).
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Depression Symptoms
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Depression will be screened using the 10-item Centre for Epidemiological Studies Depression Scale (CES-D-10).
The CES-D-10 is a short self-report scale to measure depressive symptoms in a general population.
Psychometric evaluation has shown the CES-D-10 to have high internal consistency, though with variability across populations (Cronbach's α = 0.71 to 0.90) and good construct validity (r = 0.78).
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Anxiety Symptoms
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
The 6-item State-Trait Anxiety Inventory (STAI-6) will be used to measure anxiety reflective of both adverse situations (state anxiety) and personality traits associated with higher levels of anxiety (trait anxiety).
STAI-6 produces scores like its longer 20-item version, showing good reliability (Cronbach's α = 0.82) with sensitivity to differing degrees of anxiety.
Possible scores range from 20 to 80; "normal scores" range from 34 to 36.
Higher scores represent higher amount of anxiety.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Eating Behaviour
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in eating behaviours will be assessed by questions asking if food consumption and unhealthy food consumption have changed since the onset of the pandemic via a 5-point likert scale (increased a lot to decreased a lot).
If participants indicate they have changed their food consumption, a qualitative question will ask them to describe why they think their behaviour has changed.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Sleeping Behaviour
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Participants will be asked to rate how the quantity and quality of their sleep has changed since the pandemic started via 5-point likert scales (increased a lot to decreased a lot).
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Physical Activity
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Physical activity will be assessed through the International Physical Activity Questionnaire - Short Form. The questionnaire asks about frequency and duration of vigorous (VPA) and moderate physical activity (MPA) over the past 7 days. Weekly Metabolic Equivalents (MET) minutes will be calculated based on responses. Participants will be categorized into high (>1500 MET min/week with 3+ days of VPA or >3000 METmin/week with 7+ days of MVPA); medium (5+ days of 20+ minutes of VPA per day, 5+ days with 30+ minutes of MPA per day, or 5+ days of MVPA that achieves 600+ MET min/week); low (participant does not meet other cut points). Frequency and duration of walking and sitting time are also assessed. The IPAQ has good reliability and criterion validity. Participants will also be asked if their PA and sedentary behaviour levels have changed during the pandemic (5-point likert; options: increased a lot to decreased a lot). |
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Resilience
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
The 10-item Connor-Davidson Resilience Scale (CD-RISC 10) is a widely used measure to assess self-perceived resilience.
Evaluations of the CD-RISC 10 have shown good internal consistency (Cronbach's α = 0.85), a strong positive association with the longer 25-item CD-RISC (r = 0.92).
Scores range from 0 to 40; a higher score is indicative of higher resilience.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Self-Esteem
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Self-esteem will be measured using the 10-item Rosenberg Self Esteem Scale.
The scale is a widely used measure that correlates well with other measures of self-esteem and has strong internal consistency (0.92) and test-retest reliability (0.88).
Scores range from 4 to 40; a higher score indicates higher self esteem.
Participants will also be asked how their self-esteem has changed since the beginning of the pandemic.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Loneliness
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Loneliness will be evaluated using a shortened (3 item) version of the UCLA Loneliness Scale.
This scale asks about feelings of companionship, being left out, and being isolated from others in the last month, with a 3-item list of answer options (hardly ever, some of the time, often).
This scale has good reliability (r = 0.73), validity, and internal consistency (Cronbach's α = 0.84-0.94).
The scale also showed convergent validity with other commonly used measures of loneliness.
Scores range from 1 to 9; higher scores indicate higher levels of loneliness.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Dissociative Experiences
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
The Brief Dissociative Experiences Scale is an 8-item tool that assesses the severity of dissociative experiences in adults.
The scale items are summed and averaged to describe the severity of dissociative experiences as none (0), mild (1), moderate (2), severe (3), or extreme (4).
The brief scale was found to be reliable, easy to use, and clinically useful in the DSM-5 Field Trials.
Scores range from 0 to 32; a higher score indicates a greater severity of dissociative experiences.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Coping Strategies
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Coping strategies and perceived ability to cope during the pandemic will be assessed through four self-reported questions.
Participants will be asked how well they are coping with the pandemic on a 5-point likert, options will range from 'excellent' to 'poor'.
Participants will be asked to identify things that are helping them to cope from a list of 18 items.
Current life satisfaction will be assessed with a single question with options ranging from "very satisfied" to "very dissatisfied".
Participants will also be asked to identify up to 3 things they wish they could change right now in their life.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Changes in Relationships and Belonging
Time Frame: Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Participants will be asked to self-report feelings of belonging to their local and work communities.
They will also be asked to self-report changes to the quality or stress associated with their romantic relationships and the presence of abuse.
|
Baseline, Mid-point (4-weeks), Post-intervention (8-weeks), 3-month Follow Up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-096
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsRecruiting
Clinical Trials on Trauma Informed Yoga
-
University of LethbridgeCompletedStress, Psychological | Mental Health Wellness 1 | Eating Behavior | Eating HabitCanada
-
Montana State UniversityCompletedStress | Trauma | Suicidal Ideation | Depression, AnxietyUnited States
-
Montana State UniversityCompletedStress | Depression, Anxiety | Adolescent BehaviorUnited States
-
Montana State UniversityNational Institute of General Medical Sciences (NIGMS)CompletedTrauma and Stressor Related DisordersUnited States
-
Montana State UniversityNational Institute of General Medical Sciences (NIGMS)CompletedStress | Depression, AnxietyUnited States
-
Georgia State UniversityNew York University; Kaiser Foundation Research Institute; UConn HealthCompleted
-
National University of Natural MedicineCompleted
-
York UniversityCompletedAn Online CBT, Mindfulness Meditation & Yoga (CBT-MY) Intervention for Posttraumatic Stress DisorderPTSD | Posttraumatic Stress DisordersCanada
-
Boston Medical CenterDoris Duke Charitable FoundationCompletedPregnancy | Stress, PsychologicUnited States
-
Johns Hopkins Bloomberg School of Public HealthEnrolling by invitationHIV Infections | Domestic ViolenceUnited States